<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037539</url>
  </required_header>
  <id_info>
    <org_study_id>090/2564</org_study_id>
    <nct_id>NCT05037539</nct_id>
  </id_info>
  <brief_title>Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain</brief_title>
  <official_title>Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain in Gynecologic Cancer Patients With Chronic Cancer Pain : A Randomized Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized control trial that to comparison the efficacy of injectable fentanyl in sublingual&#xD;
      route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with&#xD;
      chronic cancer pain Primary outcome : to measure pain score after drug is given&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      objective; To comparison the efficacy of injectable fentanyl in sublingual route versus oral&#xD;
      morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain&#xD;
      Population : gynecologic cancer patients with chronic cancer pain that use opioid drug for&#xD;
      basal pain and had experienced of breakthrough pain cancer in Rajavithi hospital sample size&#xD;
      : 20 person/group Method ; Randomized control trial , Prospective Intervention : group A :&#xD;
      injectable fentanyl in sublingual , group B : oral morphine syrup Primary outcome : to&#xD;
      measure pain score after drug is given at 5, 15, 30, 45, 60 and 120 min secondary outcome :&#xD;
      to record side effect of drug is given at 5, 15, 30, 45, 60 and 120 min Statistical method&#xD;
&#xD;
        -  Categorical data = Chi-square test or Fishers' exact test&#xD;
&#xD;
        -  Continuous data : comparison with Student t-test in normal deviation data and&#xD;
           Man-Whitney U- test in abnormal deviation data • Analytical data with Pearson's&#xD;
           correlation, Linear regression or Binary Logistic regression, Repeated Measures ANOVA&#xD;
           with OR (95%CI) and p-value &lt;0.05&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>after drug is given at 5 minutes</time_frame>
    <description>measure with numeric score from 0-10 point (maximum pain= 10 point)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neausea and vomiting</measure>
    <time_frame>after drug is given at 5 minutes</time_frame>
    <description>measure by asking symptom from patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ithching</measure>
    <time_frame>after drug is given at 5 minutes</time_frame>
    <description>measure by asking symptom from patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress</measure>
    <time_frame>after drug is given at 5 minutes</time_frame>
    <description>measure by respiratory rate parametor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pain, Breakthrough</condition>
  <arm_group>
    <arm_group_label>Injectable Fentanyl in Sublingual Route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Morphine Syrup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Citrate 50Mcg/Ml Inj_#1</intervention_name>
    <description>Injectable Fentanyl in Sublingual Route 50 mcg</description>
    <arm_group_label>Injectable Fentanyl in Sublingual Route</arm_group_label>
    <other_name>Fentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Oral Morphine Syrup 2.5 ml ( 5 mg)</description>
    <arm_group_label>Oral Morphine Syrup</arm_group_label>
    <other_name>morphine syrup</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gynecologic cancer patients with chronic cancer pain that use opioid drug for basal&#xD;
             pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy in fentanyl or morphine&#xD;
&#xD;
          -  abnormal cognitive function patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanvarat Tilagul</last_name>
    <role>Study Director</role>
    <affiliation>Rajavithi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thanvarat Tilagul, MD</last_name>
    <phone>0942635132</phone>
    <email>ratatime@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Lennernäs B, Hedner T, Holmberg M, Bredenberg S, Nyström C, Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005 Feb;59(2):249-53.</citation>
    <PMID>15676050</PMID>
  </reference>
  <results_reference>
    <citation>Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999 May;81(1-2):129-34.</citation>
    <PMID>10353500</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008 May;35(5):563-7. doi: 10.1016/j.jpainsymman.2007.06.012. Epub 2008 Feb 6.</citation>
    <PMID>18258412</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011 Dec;80(3):460-5. doi: 10.1016/j.critrevonc.2010.12.002. Epub 2011 Jan 6. Review.</citation>
    <PMID>21215653</PMID>
  </results_reference>
  <results_reference>
    <citation>Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013 Oct;46(4):573-80. doi: 10.1016/j.jpainsymman.2012.09.009. Epub 2013 Feb 4. Review.</citation>
    <PMID>23380337</PMID>
  </results_reference>
  <results_reference>
    <citation>Velázquez Rivera I, Muñoz Garrido JC, García Velasco P, España Ximénez de Enciso I, Velázquez Clavarana L. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Adv Ther. 2014 Jan;31(1):107-17. doi: 10.1007/s12325-013-0086-4. Epub 2014 Jan 3.</citation>
    <PMID>24385406</PMID>
  </results_reference>
  <results_reference>
    <citation>Bushnaq M, Al-Shoubaki M, Milhem M. The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer. J Palliat Med. 2009 Jun;12(6):511-4. doi: 10.1089/jpm.2009.9618.</citation>
    <PMID>19508134</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breakthrough pain</keyword>
  <keyword>Injectable Fentanyl in Sublingual Route</keyword>
  <keyword>gynecologic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

